Lexicon Pharmaceuticals LXRX Total costs & expenses
Total costs & expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's total costs & expenses?
- Lexicon Pharmaceuticals (LXRX) reported total costs & expenses of $22.1M in Q1 2026.
- How has Lexicon Pharmaceuticals's total costs & expenses changed year-over-year?
- Lexicon Pharmaceuticals's total costs & expenses decreased by 18.0% year-over-year, from $26.94M to $22.1M.
- What is the long-term trend for Lexicon Pharmaceuticals's total costs & expenses?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's total costs & expenses has grown at a 3.1% compound annual growth rate (CAGR), from $87.39M to $98.71M.
- What does total costs & expenses mean?
- The aggregate of all operating and non-operating costs incurred during the period, including research and development, selling, general, and administrative expenses. Monitoring this total provides insight into the company's overall burn rate and operational efficiency.